Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Google Secures Pentagon AI Deal for Classified Projects 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
The US International Trade Commission (ITC) upheld its preliminary ruling saying that South Korean drugmaker Daewoong Pharmaceutical Co. copied the manufacturing process of a botulinum toxin strain by local rival Medytox Inc. in Medytox Medytox
Consequently, the US trade panel ordered a 21-month ban on imports of Daewoong Pharmaceutical's botulinum products into the US.
ITC's ruling, however, reduces the initial 10-year ban prescribed by the preliminary panel that ruled that Daewoong's misappropriated trade secrets belonging to Medytox.
Medytox Inc. claimed that Daewoong's Jeuveau was developed using a trade secret stolen from it that turns the deadly botulinum toxin into a wrinkle treatment.
Daewoong denied any theft allegations or that any trade secret was involved and argued the US agency is not the proper forum to decide on the dispute.
